ChartMill · Oct 10, 2026
Johnson & Johnson (NYSE:JNJ): Dividend Quality Makes It a Durable Income Pick
JNJ dividend analysis: 3.12% yield, 8/10 dividend rating, strong profitability, and moderate health support a durable payout for income investors.
NYSE · JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$261.44
Up+$4.96 (+1.93%)
Updated Oct 10, 2026, 11:23 PM
SID Score
7.3/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 505.78B
- P/E ratio
- 20.3
- Dividend yield
- 1.97%
- 52-week range
- $200.91 – $281.07
- Volume
- 5.73M
- Avg. volume
- 8.82M
Price performance · JNJ
JNJ price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
JNJ closed at $261.44 after 21 trading sessions, down 1.56% for the selected period.
- Last close
- $261.44
- Period change
- -1.56%
- Period low
- $252.93
- Period high
- $271.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $255.09 | $261.61 | $254.985 | $261.44 | 5.73M |
| Oct 8, 2026 | $256.22 | $257.80 | $251.945 | $256.48 | 6.18M |
| Oct 7, 2026 | $256.21 | $260.68 | $255.73 | $258.45 | 5.41M |
| Oct 6, 2026 | $254.15 | $255.48 | $251.17 | $254.78 | 5.66M |
| Oct 5, 2026 | $256.00 | $256.24 | $252.51 | $252.93 | 10.03M |
| Oct 2, 2026 | $259.38 | $259.38 | $255.12 | $256.03 | 10.94M |
| Oct 1, 2026 | $263.68 | $263.975 | $258.33 | $258.66 | 8.29M |
| Sep 30, 2026 | $267.91 | $268.48 | $264.51 | $264.74 | 6.34M |
| Sep 29, 2026 | $269.11 | $271.894 | $265.5883 | $267.57 | 5.62M |
| Sep 28, 2026 | $270.17 | $273.78 | $269.27 | $271.95 | 7.19M |
| Sep 25, 2026 | $271.70 | $272.2459 | $269.2573 | $271.22 | 4.09M |
| Sep 24, 2026 | $269.52 | $275.23 | $269.01 | $270.68 | 6.32M |
| Sep 23, 2026 | $269.47 | $272.14 | $266.50 | $269.17 | 6.64M |
| Sep 22, 2026 | $267.51 | $270.10 | $265.04 | $269.19 | 5.68M |
| Sep 21, 2026 | $271.74 | $273.73 | $268.50 | $269.47 | 4.49M |
| Sep 18, 2026 | $269.45 | $272.11 | $267.1975 | $269.99 | 16.43M |
| Sep 17, 2026 | $268.00 | $270.87 | $267.11 | $270.22 | 6.57M |
| Sep 16, 2026 | $266.81 | $268.65 | $266.295 | $267.28 | 4.89M |
| Sep 15, 2026 | $265.81 | $267.20 | $260.68 | $267.20 | 5.28M |
| Sep 14, 2026 | $271.00 | $271.55 | $266.19 | $266.32 | 4.74M |
| Sep 11, 2026 | $268.03 | $270.40 | $265.25 | $265.58 | 4.71M |
Latest JNJ news
The latest Smart Investors Daily articles mentioning JNJ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JNJ research
Overview
Company profile and research snapshot.
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $207.08
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Guggenheim | Buy | — |
| Oct 6, 2026 | RBC Capital | Outperform | — |
| Oct 5, 2026 | Citigroup | Buy | — |
| Sep 29, 2026 | JP Morgan | Neutral | — |
| Sep 10, 2026 | HSBC | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.
Yahoo · Oct 9, 2026
Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim Cramer
Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ), while operating in completely different industries, factored into the discussion in Cramer’s October 2nd morning appearance. The CNBC TV host discussed the two as stocks that could be bought on the back of weakness in the economy indicated through the jobs report, which saw the US add a […]
Yahoo · Oct 9, 2026
Earnings Calendar and Analysis for This Week (June 8-12)
Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.
AI research layers
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson Stock Performance
Johnson & Johnson shares traded at $261.44, reflecting a daily decline of 0.38% per SID market data. Over the trailing twelve months, JNJ has delivered a gain of 24.64%, demonstrating sustained upward momentum in the healthcare sector. However, shorter-term performance has weakened, with the stock declining 3.97% over the past month and posting a marginal 0.19% loss over three months. The stock currently trades below its 50-day moving average of $265.22 while remaining well above its 200-day moving average of $246.62, according to SID market data. The 14-day relative strength index sits at 27.6, placing JNJ in oversold territory and suggesting recent selling pressure may be approaching exhaustion. The company's beta of 0.349 confirms its historically low volatility relative to the broader market. Average daily trading volume stands at approximately 8.82 million shares, supporting consistent liquidity for institutional positioning.
Johnson & Johnson Valuation Analysis
Johnson & Johnson carries a market capitalization of approximately $505.78 billion, positioning it among the largest healthcare companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 20.30, reflecting a moderate premium consistent with large-cap defensive healthcare names. The PEG ratio stands at 1.91, suggesting the stock is priced above its earnings growth rate on a relative basis. JNJ's price-to-book ratio of 6.43 indicates the market assigns substantial value to the company's intangible assets, including its pharmaceutical pipeline and consumer health brand portfolio. The current dividend yield of 2.45%, according to SID market data, continues to attract income-focused investors and reinforces the company's status as a Dividend Aristocrat. Within the healthcare sector, these valuation metrics reflect a business commanding premium multiples driven by diversified revenue streams, consistent cash flow generation, and a long track record of shareholder returns through dividends and buybacks.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score stands at 59 out of 100, registering a neutral signal according to SID market data. Institutional ownership conviction is notably strong, scoring a perfect 25 out of 25, indicating that major asset managers maintain robust positions in the stock. Congressional trading activity scored 12.8 out of 25, reflecting moderate engagement from lawmakers. Insider activity scored 11.8 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days, comprising 8 purchases and 12 sales. The net selling bias among insiders suggests some executives may be taking profits following the stock's 24.64% annual gain, though routine compensation-related dispositions often account for a significant portion of insider sales. Dark pool activity scored 9.5 out of 25, indicating below-average institutional block trading in off-exchange venues. The divergence between the perfect institutional score and the modest dark pool reading may suggest established holders are maintaining existing positions rather than actively accumulating new shares during the current period.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the January 2026 quarter, JNJ reported earnings per share of $2.46, narrowly missing the consensus estimate of $2.47 by one cent, resulting in a surprise of negative $0.01. The company rebounded in the April 2026 quarter, delivering $2.70 per share against estimates of $2.67, a positive surprise of $0.03. Performance strengthened further in the July 2026 quarter, with actual EPS of $2.90 exceeding the $2.85 estimate by $0.05, marking the largest beat in the trailing three-period sequence. The upcoming October 2026 quarter, scheduled for reporting on October 13, carries a consensus analyst estimate of $2.57 per share. The sequential decline in the estimate relative to the prior quarter's $2.90 actual result may reflect anticipated seasonal revenue patterns or product mix dynamics within the pharmaceutical and medtech segments.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson skews favorably, with the majority of recent analyst actions maintaining bullish ratings, per SID consensus data. On October 7, 2026, Guggenheim reiterated a Buy rating on JNJ, while Citigroup also maintained its Buy recommendation on October 5. RBC Capital reaffirmed an Outperform rating on October 6, and HSBC sustained its Buy call from September 10. The sole neutral voice among recent coverage came from JP Morgan, which maintained its Neutral rating on September 29, 2026. Notably, none of the five most recent analyst actions represented a downgrade; all were reiterations of existing positions, according to Wall Street analyst reports. The four-to-one ratio of bullish versus neutral ratings among recent coverage updates reflects broad institutional confidence in JNJ's fundamental trajectory. The clustering of reaffirmed ratings in late September and early October 2026 coincides with the approach of the company's upcoming earnings release scheduled for October 13.
